ALK-abello (AKBLF) Stock Price & Analysis

AKBLF Stock Chart & Stats

$37.23$0.98(2.70%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $36.15 - $38.31
52-Week Range: $28.60 - $43.30
Previous Close: $36.25
Volume: 100
Average Volume (3M): 74
Market Cap: $8.24B
Enterprise Value: $52.87B
Total Cash (Recent Filing): $316.00M
Total Debt (Recent Filing): $990.00M
Price to Earnings (P/E): 40.7
Beta: 0.45
Next Earnings: Nov 17, 2026 (Est.)
EPS Estimate: 0.25
Last Dividend Ex-Date: Mar 17, 2026
Dividend Yield: 0.67%

ALK-abello News

ALK-Abelló Earnings Call Highlights Growth Amid Risks

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q2 earnings call. Read on for the main highlights of the call. ALK-Abelló’s latest earnings call struck an upbeat tone as management

2M agoAKBLF 4AJ0

AKBLF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

ALK-abello A/S Class B (AKBLF) is scheduled to report 2nd quarter earnings on 08/20/2026. Regarding Q2 estimates, Wall Street analysts expect ALK-abello A/S Class B to post earnings of DKK1.50

2M agoAKBLF 4AJ0

ALK-Abello initiated with a Buy at Berenberg

Berenberg initiated coverage of ALK-Abello (AKBLF) with a Buy rating and DKK 305 price target The firm says ALK is the global market leader in allergy immunotherapy. Published first on

5M agoAKBLF 4AJ0

ALK-Abelló Lifts Outlook After Strong Q1 Call

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q1 earnings call. Read on for the main highlights of the call. ALK-Abelló’s latest earnings call struck an upbeat tone as strong

5M agoAKBLF 4AJ0

ALK-Abelló Earnings Call Signals Profitable Growth

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q4 earnings call. Read on for the main highlights of the call. ALK‑Abelló’s latest earnings call struck an upbeat tone, underscoring a

8M agoAKBLF 4AJ0

ALK-Abelló Reports Strong Q3 Growth and Upgrades Outlook

ALK-abello A/S Class B ( ($AKBLF) ) has released its Q3 earnings. Here is a breakdown of the information ALK-abello A/S Class B presented to its investors. ALK-Abelló A/S, a

11M agoAKBLF 4AJ0

ALK-abello A/S Earnings Call Highlights Growth and Challenges

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for ALK-abello A/S Class B painted

11M agoAKBLF 4AJ0

Is AKBLF a Buy, Before Earnings?

ALK-abello A/S Class B (AKBLF) is scheduled to report 3rd quarter earnings on 11/13/2025. Regarding Q3 estimates, Wall Street analysts expect ALK-abello A/S Class B to post earnings of DKK1.00

11M agoAKBLF 4AJ0

ALK-abello Earnings Call: Strong Growth Amid Challenges

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q2 earnings call. Read on for the main highlights of the call. The recent earnings call for ALK-abello A/S Class B painted

1y agoAKBLF 4AJ0

ALK-Abelló A/S Reports Strong Q2 2025 Earnings Growth

ALK-abello A/S Class B ( ($AKBLF) ) has released its Q2 earnings. Here is a breakdown of the information ALK-abello A/S Class B presented to its investors. ALK-Abelló A/S, a

1y agoAKBLF 4AJ0

ALK-abello A/S Class B (AKBLF) Q2 Earnings Cheat Sheet

ALK-abello A/S Class B (AKBLF) is scheduled to report 2nd quarter earnings on 08/21/2025. Regarding Q2 estimates, Wall Street analysts expect ALK-abello A/S Class B to post earnings of DKK1.30

1y agoAKBLF 4AJ0

ARS Pharmaceuticals Air Lease ALK-Abello

ARS Pharmaceuticals (SPRY) announced that the company has entered into an agreement with ALK-Abello A/S (AKBLF) to co-promote neffy, the only approved needle-free treatment for Type I allergic reactions including

1y agoSPRY AKBLF

ALK-Abello says FDA approves label expansion for Odactra

ALK announced that the U.S. FDA expanded its indication of Odactra for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, to now include children ages 5

1y agoAKBLF 4AJ0

ALK-Abello upgraded to Buy from Hold at Jefferies

Jefferies upgraded ALK-Abello (AKBLF) to Buy from Hold with a price target of DKK 185, up from DKK 153. The firm has become more positive on ALK’s growth profile, saying

1y agoAKBLF 4AJ0

AKBLF FAQ

What was ALK-abello’s price range in the past 12 months?

ALK-abello lowest stock price was $28.60 and its highest was $43.30 in the past 12 months.

What is ALK-abello’s market cap?

ALK-abello’s market cap is $8.24B.

When is ALK-abello’s upcoming earnings report date?

ALK-abello’s next earnings report is estimated for Nov 17, 2026 (not yet confirmed), which is in 16 days.

How were ALK-abello’s earnings last quarter?

ALK-abello released its earnings results on Aug 20, 2026. The company reported $0.224 earnings per share for the quarter.

Is ALK-abello overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does ALK-abello pay dividends?

ALK-abello pays a Notavailable dividend of $0.244 which represents an annual dividend yield of 0.67%. See more information on ALK-abello dividends here

What is ALK-abello’s EPS estimate?

ALK-abello’s EPS estimate is 0.25.

How many shares outstanding does ALK-abello have?

ALK-abello has 202,567,200 shares outstanding.

What happened to ALK-abello’s price movement after its last earnings report?

ALK-abello reported an EPS of $0.224 in its last earnings report. Following the earnings report the stock price went down -4.32%.

Which hedge fund is a major shareholder of ALK-abello?

Hedge funds hold ALK-abello shares: the largest hedge-fund position in ALK-abello is 70,122,355 shares, and hedge funds increased their holdings by 3.0K shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ALK-abello

ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.

ALK-abello (AKBLF) Earnings & Revenues

Historic Earnings Reports

AKBLF Company Deck

AKBLF Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call emphasized strong top-line and cash-generation performance driven by tablet momentum, robust pipeline progress (peanut Phase III planning, China ACARIZAX readout) and an upgraded revenue range, while also acknowledging near-term cost increases and regulatory/market-access headwinds—most notably the German rebate increase and U.K. rollout delays for neffy. Management outlined mitigation plans and maintained long-term ambitions, suggesting confidence in growth despite some regional and timing uncertainties.

View all AKBLF earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	3	4
Technical Analysis	3	3	4
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to AKBLF
Company	Price & Change	Follow
INOInovio Pharmaceuticals
ACRSAclaris Therapeutics
EBSEmergent Biosolutions
NVSNovartis
BMYBristol-Myers Squibb

Compare AKBLF Stocks >

Ownership Overview

3.75% Mutual Funds
91.69% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

AKBLF Stock Chart & Stats

ALK-abello News

ALK-Abelló Earnings Call Highlights Growth Amid Risks

AKBLF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

ALK-Abello initiated with a Buy at Berenberg

ALK-Abelló Lifts Outlook After Strong Q1 Call

ALK-Abelló Earnings Call Signals Profitable Growth

ALK-Abelló Reports Strong Q3 Growth and Upgrades Outlook

ALK-abello A/S Earnings Call Highlights Growth and Challenges

Is AKBLF a Buy, Before Earnings?

ALK-abello Earnings Call: Strong Growth Amid Challenges

ALK-Abelló A/S Reports Strong Q2 2025 Earnings Growth

ALK-abello A/S Class B (AKBLF) Q2 Earnings Cheat Sheet

ARS Pharmaceuticals Air Lease ALK-Abello

ALK-Abello says FDA approves label expansion for Odactra

ALK-Abello upgraded to Buy from Hold at Jefferies

AKBLF FAQ

Company Description

ALK-abello

ALK-abello (AKBLF) Earnings & Revenues

AKBLF Company Deck

AKBLF Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive